Introduction
============

Lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1), the major receptor for oxidized low-density lipoprotein (oxLDL) in endothelial cells^[@bib1])^, is a key molecule in the pathogenesis of atherosclerosis^[@bib2])^. Basal expression of LOX-1 is very low and up-regulation of endothelial LOX-1 is induced via oxLDL in proatherogenic conditions^[@bib3],\ [@bib4])^. Several reports showed that high levels of soluble LOX-1 (sLOX-1) are generated through proteolytic cleavage of the extracellular domain of LOX-1^[@bib5])^ and that sLOX-1 can be used as a diagnostic biomarker of acute coronary syndrome^[@bib6])^. On the other hand, the clinical implications of serum sLOX-1 levels in acute stroke patients have not been clarified. We hypothesized that serum sLOX-1 levels would be also used as a biomarker of acute stroke as in the case of acute coronary syndrome.

Aim
===

We aimed to cross-sectionally examine the serum sLOX-1 levels in acute stroke patients compared with age- and sex-matched healthy controls according to stroke subtype.

Methods
=======

Subjects
--------

We subsequently enrolled 377 patients with stroke (251 men and 126 women; 40--79 years old), 250 with ischemic stroke and 127 with intracerebral hemorrhage (ICH), who were admitted to the National Cerebral and Cardiovascular Center (NCVC) within 3 days after the onset from August 2008 to August 2010.

As controls, we randomly selected age- and sex-matched subjects without a past history of cardiovascular disease according to stroke subtype. Controls were randomly selected from the participants of the Suita study, which is a community-based cohort study conducted by NCVC, ongoing since 1989. Control subjects were from among those who had visited NCVC for follow-up survey from April 2006 to December 2007. The details of the Suita study were previously described^[@bib7])^.

This study was approved by the Institutional Research and Ethics Committee of NCVC, Suita, Japan. Informed consent was obtained from all participants.

Clinical Examinations
---------------------

The following information was collected from medical records of the stroke patients: height; weight; results of routine blood examinations including lipid profiles, high sensitive-C reactive protein (hs-CRP), medication for hypertension, dyslipidemia, and diabetes; and stroke severity assessed by National Institutes of Health Stroke Scale (NIHSS) scores on admission and stroke subtypes. Subtypes of ischemic stroke, such as atherothrombotic brain infarction (ABI; *n* = 43), lacunar (*n* = 56), cardioembolic (*n* = 59), and other types (*n* = 92), were diagnosed as previously described^[@bib8])^. For controls, similar information was extracted from the Suita Study.

Morning blood samples after overnight fasting (within 3 days after onset of stroke for cases) were collected to be kept at −80°C until measurement of sLOX-1 levels. In all patients, serum lipids levels were immediately measured at the same in-hospital laboratory as previously described^[@bib8])^. Serum hs-CRP levels were measured using an ultra-sensitive latex-enhanced immunoassay with an automatic analyzer (BN ProSpec System, Siemens, Munich, Germany). sLOX-1 levels were measured by ELISA using 2 monoclonal antibodies against LOX-1 as described previously^[@bib9])^ but using mouse anti-human LOX-1 monoclonal antibody (MAB1798, R&D, Minneapolis, Minnesota, USA) instead of TS92.

Statistical Analysis
--------------------

All analyses were conducted using SAS version 9.3 (SAS Institute, Cary, California, USA). Inter-quartile ranges of sLOX-1 levels were shown with associated *p* values using the Wilcoxon signed rank sum test for inter-group comparison. For other continuous variables, means and standard deviations were shown with *p* values using paired *t*-test. Proportions were compared between groups using McNemar\'s test. In addition, conditional and unconditional logistic regression analyses were used to calculate odds ratios and 95% confidence intervals for high sLOX-1 levels by each stroke subtype, which were compared with age- and sex-matched controls and adjusted for age, cigarette smoking, body mass index, hypertension, diabetes, and dyslipidemia. High sLOX-1 level was defined as 1177 ng/L (corresponding to the 80th percentile of all stroke patients) or more. A *p* value of \< 0.05 was considered to indicate statistical significance.

Results
=======

Median values of serum sLOX-1 in patients with acute stroke were significantly higher than those in controls: 526 vs. 486 ng/L in ischemic stroke (*p* = 0.009) and 720 vs. 513 ng/L in ICH (*p* \< 0.001) (**[Table 1](#T1){ref-type="table"}**). In patients with ABI, the median sLOX-1 levels were significantly higher than those in controls: 641 vs. 496 ng/L (*p* = 0.02) (**[Table 2](#T2){ref-type="table"}**). There were no significant differences between patients and controls in sLOX-1 levels in the other subtypes of ischemic stroke. Ischemic stroke and ICH were associated with high levels of sLOX-1 after adjusting for age, cigarette smoking, body mass index, hypertension, diabetes, and dyslipidemia (odds ratio, 3.80 in ischemic stroke; 5.97 in ICH) (**[Table 3](#T3){ref-type="table"}**).

###### Comparison of soluble LOX-1 (sLOX-1) levels between stroke cases and age-matched controls by stroke subtypes

                           Ischemic stroke     Intracerebral hemorrhage                                                   
  ------------------------ ------------------- -------------------------- ---------- ------------------- ---------------- ----------
  Number                   250                 250                                   127                 127              
  Age, years               67.3 (8.6)          66.5 (9.0)                 −          66.5 (8.6)          66.0 (8.7)       −
  Men (%)                  70                  70                         −          61                  61               −
  BMI (kg/m^2^)            23.3 (3.3)          22.9 (3.0)                 0.22       23.1 (4.1)          22.8 (2.8)       0.57
  sLOX-1 (ng/L)            526 (330, 883)      486 (321, 703)             0.009      720 (459, 1125)     513 (307, 770)   \< 0.001
  sLOX-1 ≥ 1177 ng/L (%)   18                  6                          \< 0.001   24                  7                \< 0.001
  TC (mg/dL)               195 (41)            201 (31)                   0.04       193 (43)            203 (29)         0.03
  HDL-C (mg/dL)            51 (14)             59 (16)                    \< 0.001   56 (16)             61 (16)          0.02
  hs-CRP (mg/dL)           0.10 (0.04, 0.25)   −                          −          0.10 (0.05, 0.25)   −                −
  Cigarette smoking (%)    30                  19                         0.003      17                  18               0.87
  Hypertension (%)         79                  33                         \< 0.001   92                  36               \< 0.001
  Dyslipidemia (%)         52                  30                         \< 0.001   34                  31               0.55
  Diabetes mellitus (%)    31                  10                         \< 0.001   28                  12               0.002
  NIHSS score              4 (2, 7)            −                          −          12 (5, 18)          −                −

BMI means body mass index. TC means total cholesterol. HDL-C means HDL cholesterol. hs-CRP means high sensitive-C reactive protein. sLOX-1 means soluble LOX-1. High soluble LOX-1 (sLOX-1) level was defined as 1177 ng/L (corresponding of the 80th percentile of all stroke patients) or more. In sLOX-1, hs-CRP, and NIHSS score, median (inter-quartile range) are shown.

Data are mean (standard deviation) unless noted otherwise.

###### Comparison of soluble LOX-1 (sLOX-1) levels between stroke cases and age-matched controls by subtypes of ischemic stroke

                          Atherothrombotic brain infarction   Cardioembolic stroke                                                  
  ----------------------- ----------------------------------- ---------------------- ---------- ------------------ ---------------- ----------
  Number                  43                                  43                     −          59                 59               −
  Men (%)                 86                                  86                     −          47                 47               −
  Age, years              69.1 (7.5)                          68.5 (8.0)             −          67.9 (7.4)         66.9 (7.9)       −
  BMI (kg/m^2^)           23.6 (3.2)                          22.7 (3.5)             0.22       23.4 (3.2)         22.6 (2.8)       0.33
  sLOX-1 (ng/L)           641 (429, 1302)                     496 (337, 781)         0.02       442 (255, 840)     462 (333, 652)   0.46
  sLOX-1 .1177 ng/L (%)   28                                  5                      0.01       19                 7                0.07
  TC (mg/dL)              202 (45)                            193 (33)               0.27       189 (36)           210 (27)         \< 0.001
  HDL-C (mg/dL)           48 (14)                             61 (16)                \< 0.001   54 (15)            58 (16)          0.08
  hs-CRP (mg/dL)          0.13 (0.05, 0.34)                   −                      −          0.13 (0.04,0.41)   −                −
  Cigarette Smoking       40                                  28                     0.25       15                 14               0.8
  Hypertension (%)        91                                  33                     \< 0.001   68                 24               \< 0.001
  Dyslipidemia (%)        74                                  23                     \< 0.001   39                 36               0.68
  Diebetes mellitus (%)   42                                  12                     \< 0.001   20                 7                0.03
  NIHSS score             4 (2, 6)                            −                      −          8 (3, 19)          −                −

                           Lacunar infarction   Other types of infarction                                                   
  ------------------------ -------------------- --------------------------- ---------- ------------------- ---------------- ----------
  Number                   56                   56                          −          92                  92               −
  Men (%)                  77                   77                          −          72                  72               −
  Age, years               66.1 (8.7)           65.7 (9.1)                  −          66.7 (9.7)          65.9 (9.8)       −
  BMI (kg/m^2^)            23.5 (3.2)           22.9 (2.7)                  0.33       22.9 (3.5)          23.3 (3.1)       0.48
  sLOX-1 (ng/L)            529 (341, 743)       558 (302, 850)              0.67       526 (312, 919)      463 (312, 705)   0.07
  sLOX-1 ≥ 1177 ng/L (%)   9                    5                           0.48       18                  5                0.01
  TC (mg/dL)               197 (43)             196 (27)                    0.87       195 (40)            203 (33)         0.11
  HDL-C (mg/dL)            52 (14)              54 (13)                     0.41       51 (13)             62 (17)          \< 0.001
  hs-CRP (mg/dL)           0.09 (0.05, 0.20)    −                           −          0.09 (0.03, 0.21)   −                −
  Cigarette Smoking        30                   21                          0.25       34                  16               0.004
  Hypertension (%)         80                   38                          \< 0.001   80                  37               \< 0.001
  Dyslipidemia (%)         48                   29                          0.04       52                  30               0.003
  Diebetes mellitus (%)    27                   9                           0.01       36                  11               \< 0.001
  NIHSS score              3 (2, 5)             −                           −          3 (2, 6)            −                −

BMI means body mass index. TC means total cholesterol. HDL-C means HDL cholesterol. hs-CRP means high sensitive-C reactive protein. sLOX-1 means soluble LOX-1. High soluble LOX-1 (sLOX-1) level was defined as 1177 ng/L (corresponding of the 80th percentile of all stroke patients) or more. In sLOX-1, hs-CRP, and NIHSS score, median (inter-quartile range) are shown.

Data are mean (SD) unless noted otherwise.

###### Adjusted odds ratios for high soluble LOX-1 (sLOX-1) level in stroke patients compared to control subjects

                                         Conditional Logistic   Unconditional Logistic          
  -------------------------------------- ---------------------- ------------------------ ------ -------------
  All brain infarction (*n* = 250)                                                              
        Model 1                          3.34                   1.73--6.44               3.77   2.01--7.09
        Model 2                          3.28                   1.68--6.39               3.67   1.94--6.94
        Model 3                          11.32                  2.17--59.18              3.8    1.86--7.74
  Intracerebral hemorrhage (*n* = 127)                                                          
        Model 1                          4.29                   1.79--10.25              4.26   1.93--9.39
        Model 2                          5.20                   1.87--14.45              4.20   1.90--9.26
        Model 3                          19.30                  2.12--175.52             5.97   2.13--16.77

Model 1: adjusted for age

Model 2: adjusted for Model 1+body mass index, cigarette smoking

Model 3: adjusted for model 2+hypertension, diabetes and dyslipidemia

High soluble LOX-1 (sLOX-1) level was defined as 1177 ng/L (corresponding to the 80th percentile of all stroke patients) or more.

Discussion
==========

This is the first study to be shown that serum sLOX-1 concentrations in patients with acute stroke were higher than age- and sex-matched controls.

LOX-1 is primarily expressed in endothelial cells, and several studies have revealed that it is also expressed in macrophages and smooth muscle cells^[@bib10])^. Cellular uptake of oxLDL via LOX-1 by macrophage and smooth muscle cells was demonstrated to be involved in atherogenic reactions, such as apoptosis, and expression of matrix metalloproteinases^[@bib4],\ [@bib11])^. Elevated levels of sLOX-1 are considered to reflect the increased expression of LOX-1, and it was suggested that high levels of sLOX-1 could be a biomarker for vulnerability of atherosclerotic plaques^[@bib6])^. Peak levels of sLOX-1 in patients with acute coronary syndrome were reported to occur within one day after admission to hospital^[@bib6])^. In the present study, significant increases in serum sLOX-1 levels were observed in patients with ABI compared with those in controls. Ogata *et al* ^[@bib12])^ showed that the rupture of an atheromatous plaque can cause thrombotic occlusion of a stenotic internal carotid artery as the onset of acute coronary syndrome; therefore, high levels of sLOX-1 in patients with ABI may indicate atherogenic reactions as the underlying mechanism for the onset of ABI.

In this study, more than 90% of patients with ICH had hypertension. Up-regulation of LOX-1 expression in the cortex of spontaneously hypertensive rats was implicated to induce neuronal apoptosis^[@bib13])^. In contrast, the contribution of LOX-1 to hypertensive ICH has not been clarified. Colocalization of LOX-1 and matrix metalloproteinases were reported in a patient with ruptured and unruptured multiple dissections of the middle cerebral artery^[@bib14])^, and extremely high sLOX-1 levels were shown to be present in patients with acute aortic dissection^[@bib15])^. We reported that cultured bovine aortic endothelial cells and Chinese hamster ovary cells expressing bovine LOX-1 bound and phagocytosed aged red blood cells and dead cells, apart from oxLDL as a ligand for LOX-1^[@bib16])^. In addition, the binding of LOX-1 ligands including oxLDL and CRP usually up-regulates the expression of LOX-1. These findings suggest that LOX-1 would bind red blood cells of ruptured hematoma in the brain tissues after the onset of ICH, causing the upregulation of sLOX-1 as well as LOX-1 expression in the present study.

The present study has several limitations. First, changes in sLOX-1 levels before and after the onset of stroke have not been examined because this is a cross-sectional study. Second, variation in sLOX-1 levels could be large, and the power to estimate the differences may not be adequate because of the small sample size. Further examinations with a large number of cases are required to clarify the role of sLOX-1 in each type of ischemic stroke. Third, delay in blood sampling in the present study could underestimate the levels of sLOX-1 because peak levels of sLOX-1 in acute coronary syndrome were reported within one day after admission.

Conclusion
==========

The present study showed that acute stroke was associated with high levels of sLOX-1 compared with age- and sex-matched controls. High levels of sLOX-1 can be useful as biomarkers for acute stroke. Further studies are required to clarify the contribution of sLOX-1 to the pathogenesis of stroke.
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